OR WAIT 15 SECS
Dry media powder for the production of biotherapeutics and vaccines will be produced in a new facility in Scotland, in addition to an existing facility in New York.
Thermo Fisher Scientific expanded its campus in Inchinnan, Scotland, by adding a facility to manufacture a proprietary dry media powder known as Gibco Advanced Granulation Technology (AGT). AGT products are animal-origin free, single-component, particulate-free powders for chemically defined cell culture. The AGT dry-media format, an alternative to traditional liquid media, is used to manufacture biologics, including vaccines and anti-cancer therapeutics.
The £14 million (USD 22.25 million) investment increases the assurance of supply for customers and complements another Thermo Fisher facility in Grand Island, New York, where AGT is also manufactured. The new facility will add to the Inchinnan site’s existing manufacturing operations, which produce liquid media for a range of research and production applications.
“This is a strategically important facility that will secure supplies for our target markets all over the world,” said Mark Smedley, president of Europe, Middle East, and Africa, Life Sciences Solutions, for Thermo Fisher. This investment is linked to ongoing support from Scottish Enterprise (Scotland's main economic development agency), to assist Thermo Fisher in expanding the company’s global manufacturing network.
Source: Thermo Fisher Scientific